MedTrace Logo

Study the Role of Stem Cell in Curing Drug Induced Liver Injury in Metastatic Breast Cancer (MBC)

NCT01231022 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 52

Last updated 2015-07-29

No results posted yet for this study

Summary

The investigators want to know the role of Peripheral hematopoietic stem cell infusion in avoiding Drug Induced Liver Injury,and also try to research SNPs genotyping associated with Drug Induced Liver Injury.

Conditions

  • Breast Neoplasms
  • Neoplasm Metastasis

Sponsors & Collaborators

  • Peking University Cancer Hospital & Institute

    lead OTHER

Principal Investigators

  • XU LIANG, MD and PhD · Peking University Cancer Hospital & Institute

  • JUN REN, MD and PhD · Peking University Cancer Hospital & Institute

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2011-06-30
Completion
2013-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01231022 on ClinicalTrials.gov